AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026

Core Insights - AC Immune is hosting an industry symposium focused on a precision prevention approach to Parkinson's disease, drawing lessons from Alzheimer's disease [1][5] - The company will present its first-in-class TDP-43 PET-tracer, ACI-19626, at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2026) [2][5] Symposium Details - The symposium titled "From Treatment to Prevention in Parkinson's Disease" is scheduled for March 18, 2026, from 8:40 to 10:40 am CET at Hall A1 [3] - Key presentations include: - Prof. Catherine Mummery discussing α-synuclein pathophysiology [3] - Werner Poewe on misfolding of α-synuclein as a fluid biomarker [3] - Günther Staffler presenting interim results of the Phase 2 VacSYn trial of ACI-7104.056 [3] - Francesca Capotosti on intracellular targeting of α-synuclein with Morphomer small molecules [3] - A Q&A session will follow the presentations, and a replay will be available on AC Immune's website [3] Company Overview - AC Immune SA is a clinical-stage biopharmaceutical company specializing in precision prevention for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases [7] - The company utilizes two clinically validated technology platforms, SupraAntigen® and Morphomer®, to develop a pipeline of first- and best-in-class assets [7] - AC Immune has established strategic partnerships with leading pharmaceutical companies, resulting in over $4.5 billion in potential milestone payments and royalties [7]